AR008747A1 - Uso de agentes neuroprotectores para la manufactura de un medicamento y dicho medicamento. - Google Patents

Uso de agentes neuroprotectores para la manufactura de un medicamento y dicho medicamento.

Info

Publication number
AR008747A1
AR008747A1 ARP960105543A ARP960105543A AR008747A1 AR 008747 A1 AR008747 A1 AR 008747A1 AR P960105543 A ARP960105543 A AR P960105543A AR P960105543 A ARP960105543 A AR P960105543A AR 008747 A1 AR008747 A1 AR 008747A1
Authority
AR
Argentina
Prior art keywords
rapamycin
medicinal product
manufacturing
diels alder
agents
Prior art date
Application number
ARP960105543A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR008747A1 publication Critical patent/AR008747A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El uso de agentes neuroprotectores para la manufactura de un medicamento util para la inhibicion de la muerte celular neuronal que comprende unacantidad efectiva de un compuesto seleccionado del grupo que consiste en rapamicina, rapamicinaaducto 1,3-Diels Alder con feniltriazolindiona,rapamicina 42-éster con 4-[[4-(dimetilamino)fenil]azo]ácido bencenosulfonico, rapamicina aducto 1,3-Diels Alder con metiltriazolindiona, y rapamicin-O--bencil-27-oxima, y un portador farmacéuticamenteaceptable, y dicho medicamento.
ARP960105543A 1995-12-07 1996-12-06 Uso de agentes neuroprotectores para la manufactura de un medicamento y dicho medicamento. AR008747A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US833795P 1995-12-07 1995-12-07

Publications (1)

Publication Number Publication Date
AR008747A1 true AR008747A1 (es) 2000-02-23

Family

ID=21731060

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960105543A AR008747A1 (es) 1995-12-07 1996-12-06 Uso de agentes neuroprotectores para la manufactura de un medicamento y dicho medicamento.

Country Status (23)

Country Link
EP (1) EP0778023B1 (es)
JP (1) JPH09183727A (es)
KR (1) KR970032856A (es)
CN (1) CN1112925C (es)
AR (1) AR008747A1 (es)
AT (1) ATE234095T1 (es)
AU (1) AU700653B2 (es)
BR (1) BR9605895A (es)
CA (1) CA2192298A1 (es)
CZ (2) CZ6498A3 (es)
DE (1) DE69626610T2 (es)
DK (1) DK0778023T3 (es)
ES (1) ES2188730T3 (es)
HU (1) HUP9603370A3 (es)
IL (1) IL119778A (es)
MX (1) MX9606131A (es)
NO (1) NO309966B1 (es)
NZ (1) NZ299888A (es)
PT (1) PT778023E (es)
SI (1) SI0778023T1 (es)
SK (1) SK154796A3 (es)
TW (1) TW427904B (es)
ZA (1) ZA9610245B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002535A1 (en) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) * 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
WO2001079177A1 (en) * 2000-04-17 2001-10-25 Gpi Nil Holdings, Inc. Cyclic diaza compounds for treating neurodegenerative disorders
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
UA78529C2 (en) 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
WO2004091633A1 (en) * 2003-04-09 2004-10-28 Wyeth Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof
DE602004029146D1 (de) 2003-04-09 2010-10-28 Wyeth Llc Derivate von 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkylphosphonsäure und deren verwendung als n-methyl-d-aspartat- (nmda-) rezeptorantagonisten
WO2004089369A2 (en) * 2003-04-11 2004-10-21 Cambridge University Technical Services Limited Methods and means for treating protein conformational disorders
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
GT200400213A (es) 2003-10-22 2007-09-05 Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
BRPI0519495A2 (pt) 2004-12-20 2009-02-03 Wyeth Corp composto ou um sal farmaceuticamente aceitÁvel do mesmo, uso de um composto, e, mÉtodo para preparar um composto
KR20070090931A (ko) 2004-12-20 2007-09-06 와이어쓰 라파마이신 유도체 및 신경계장애의 치료에서의 그의 용도
JP4857071B2 (ja) * 2006-10-12 2012-01-18 潤平 笹部 筋萎縮性側策硬化症（ａｌｓ）の検出方法
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
BRPI1010655A2 (pt) * 2009-04-10 2019-09-03 Qi Haiyan novos agentes antienvelhecimento e métodos para identificá-los
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
CA2768710A1 (en) * 2009-07-24 2011-01-27 Institut National De La Recherche Scientifique Combinations of curcuminoids and mtor inhibitors for the treatment of tauopathies
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US9121859B2 (en) 2012-12-04 2015-09-01 Siemens Healthcare Diagnostics Inc. Compounds and methods for determination of FKBP-binding immunosuppressant drugs
CN113209101A (zh) 2013-06-05 2021-08-06 法奈克斯公司 用于组合的活性药物成分的稳定口服溶液
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
JP2021502971A (ja) * 2017-11-15 2021-02-04 ヴァンダービルト ユニヴァーシティ リソソーム機能の改善および神経変性疾患の治療のための方法および組成物
CN114366738A (zh) * 2021-12-20 2022-04-19 中国人民解放军军事科学院军事医学研究院 雷帕霉素在促进神经干细胞扩增中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5260299A (en) * 1992-03-05 1993-11-09 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation

Also Published As

Publication number Publication date
KR970032856A (ko) 1997-07-22
HU9603370D0 (en) 1997-01-28
CN1112925C (zh) 2003-07-02
SK154796A3 (en) 1997-09-10
DE69626610D1 (de) 2003-04-17
NZ299888A (en) 2001-02-23
ES2188730T3 (es) 2003-07-01
CZ354496A3 (cs) 1998-03-18
EP0778023A1 (en) 1997-06-11
BR9605895A (pt) 1998-08-18
MX9606131A (es) 1997-08-30
DK0778023T3 (da) 2003-06-30
PT778023E (pt) 2003-06-30
ATE234095T1 (de) 2003-03-15
CN1159915A (zh) 1997-09-24
IL119778A0 (en) 1997-03-18
CZ6498A3 (cs) 1998-06-17
AU700653B2 (en) 1999-01-14
ZA9610245B (en) 1998-06-05
TW427904B (en) 2001-04-01
SI0778023T1 (en) 2003-08-31
CA2192298A1 (en) 1997-06-08
HUP9603370A2 (en) 1997-05-28
IL119778A (en) 1999-07-14
DE69626610T2 (de) 2003-10-02
JPH09183727A (ja) 1997-07-15
AU7417896A (en) 1997-06-12
EP0778023B1 (en) 2003-03-12
HUP9603370A3 (en) 1998-12-28
NO965238L (no) 1997-06-09
NO309966B1 (no) 2001-04-30
NO965238D0 (no) 1996-12-06

Similar Documents

Publication Publication Date Title
AR008747A1 (es) Uso de agentes neuroprotectores para la manufactura de un medicamento y dicho medicamento.
ME00318B (me) Nova kompozicija i njena upotreba
FR2752732B1 (fr) Forme galenique a liberation prolongee de milnacipran
AR031973A1 (es) Agonistas de los receptores beta2-adrenergicos, una composicion farmaceutica, y uso de dichos agonistas para la manufactura de un medicamento
GR3015737T3 (en) Multi-layered controlled release formulation.
AR006678A1 (es) Derivados de macrolidas triciclicas, una composicion farmaceutica que los contiene, uso de los mismos para preparar medicamentos y procedimientopara su preparacion
PT1017391E (pt) Formulacao de comprimidos de libertacao prolongada para tratar a doenca de parkinson
ATE259823T1 (de) Tricyclische erythromycinderivate
CA2041417A1 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
WO2001035940A3 (en) Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
AR013864A1 (es) COMPOSICIONES FARMACEUTICAS PARA LA PREVENCIoN PRIMARIA DEL CANCER DE PECHO EN UNA MUJER POST MENOPÁUSICA Y SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO
NZ514558A (en) Viral treatment
ATE197401T1 (de) Chinazolinon-arzneimittel sowie deren verwendung
AR024118A1 (es) Compuesto de oxazolidinona biciclica como agentes antibacterianos, composicion farmaceutica que lo contiene y uso del mismo para la manufactura de un medicamento
ATE450254T1 (de) Schwimmende pharmazeutische zusammensetzung mit einer aktiven phase und einer inaktiven phase
GB0010446D0 (en) Pharmaceutical formulation
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
KR910007531A (ko) 15-케토-프로스타글란딘 화합물을 이용한 간 담즙성 질병의 치료
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
KR970061248A (ko) 알츠하이머병 치료용 1, 1, 2-트리페닐부트-1-엔 유도체
FR2766088B1 (fr) Dispositifs a liberation controlee d'un agent pharmaceutique, leur fabrication par co-extrusion et article intermediaire
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
CA2209673A1 (en) Solid medicament form with active agent distributed in polymer material
ES2170168T3 (es) Composiciones recubiertas entericamente de derivados de 1,5-benzodiacepina con actividad antagonista o agonista de cck.
ES2186909T3 (es) Agentes antipaludicos y antibabesiosis y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal